Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Escitalopram.

Sarah Aronson¹, Pedro Delgado

¹University Center for Psychiatry in Medical Practice, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA. sarah.aronson@uhhs.com

Drugs of Today (Barcelona, Spain : 1998)

|March 27, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mass spectrometry-based proteomics to study gastric carcinogenesis: pathophysiological molecular characterization.

Scientific reports·2026

Same author

Quality improvement for self-management: the DIALOG+QI framework.

BMJ open quality·2026

Same author

Electroencephalographic and cognitive task analysis of working memory and attention in athletes: A systematic review.

Psychology of sport and exercise·2025

Same author

Chronic Posttraumatic Nail Reconstruction with an Eponychium Flap: Technique Description and Case Series.

Journal of hand surgery global online·2025

Same author

Enhanced Photocatalytic Proton-Coupled Electron Transfer by Ligand Design in a Zr Coordination Cage.

ChemSusChem·2025

Same author

Patient safety culture in South America: a cross-sectional study.

BMJ open quality·2023

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is effective for major depression. Clinical data support its efficacy and tolerability, comparable to other SSRIs.

Area of Science:

Pharmacology
Neuroscience
Psychiatry

Background:

Escitalopram is the S-enantiomer of citalopram, a selective serotonin reuptake inhibitor (SSRI).
The S-enantiomer is believed to be responsible for the antidepressant efficacy of citalopram.
Escitalopram has been approved by the FDA for treating major depressive disorder.

Purpose of the Study:

To review preclinical and clinical studies of escitalopram.
To focus on its therapeutic action profile and tolerability.
To compare its efficacy and safety with placebo and other SSRIs.

Main Methods:

Review of preclinical and clinical studies.
Analysis of in vitro radioligand binding data.
Comparison of efficacy, tolerability, and adverse effects with citalopram and other SSRIs.

Related Experiment Videos

Main Results:

Escitalopram is the most selective SSRI based on in vitro data.
Clinical data support the antidepressant efficacy of escitalopram.
Its therapeutic profile is comparable to citalopram and other SSRIs regarding efficacy and tolerability.
Escitalopram is well-tolerated, safe in overdose, and has a low incidence of adverse effects and drug interactions.

Conclusions:

Escitalopram demonstrates significant efficacy in treating major depression.
It offers a favorable tolerability and safety profile.
Escitalopram represents a valuable therapeutic option within the SSRI class for major depression.